IGF-1 LR3 1mg is a long acting insulin like growth factor research peptide supplied as a single lyophilized vial. Manufactured for consistent potency, stability, and controlled research applications.
Pack Size Selected: Single Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
IGF-1 LR3 is a synthetic long acting analogue of Insulin Like Growth Factor 1 (IGF-1), engineered with two structural modifications that substantially alter its pharmacokinetic profile from native IGF-1. An arginine substitution at position 3 and a 13 amino acid N terminal extension that together produce a compound with dramatically reduced insulin like growth factor binding protein (IGFBP) affinity and a significantly extended half-life. Hudson Science’s formulation supplies 1mg as a lyophilized vial, a standard research unit for IGF analogues where precise low concentration handling is critical. Preserving peptide structural integrity and potency across storage conditions until reconstitution.
The structural modifications defining IGF-1 LR3 produce a pharmacological profile that is distinctly more potent and longer acting than native IGF-1 in research contexts. Native IGF-1’s extensive IGFBP binding sequesters a significant fraction of administered compound in circulation, reducing receptor available concentration. IGF-1 LR3’s reduced IGFBP affinity, estimated at approximately 1000 fold lower than native IGF-1 maintains a substantially higher free bioavailable fraction per administered dose, with the N-terminal extension contributing additional receptor activation enhancement. The combined effect produces an estimated half-life of approximately 20–30 hours compared to native IGF-1’s 12–15 hours. A meaningful research advantage for protocols examining sustained IGF-1 receptor activation without the frequent administration that native IGF-1’s IGFBP-sequestered profile would require.
IGF-1 LR3 and IGF-DES represent complementary rather than interchangeable research tools within CSD’s IGF analogue range despite both operating through reduced IGFBP binding mechanisms. IGF-DES achieves IGFBP reduction through N-terminal truncation, removing the first three amino acids, producing very high local receptor potency with a shorter active window suited to localized tissue research. IGF-1 LR3’s N-terminal extension and arginine substitution produce sustained systemic IGF-1 receptor activation with a longer half-life suited to research examining extended anabolic pathway stimulation, satellite cell recruitment, skeletal muscle hypertrophy mechanisms, and systemic IGF-1 axis activity across multiple tissue types simultaneously.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks both IGF-1 LR3 and IGF-DES as complementary IGF analogue research compounds, alongside the full GH secretagogue range including GHRP-2, GHRP-6, Ipamorelin, Hexarelin, Sermorelin, Tesamorelin, CJC-1295, and rHGH. Giving researchers access to the complete growth hormone and IGF axis research compound family from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside IGF-DES and HGH in comparative IGF receptor binding and anabolic signaling studies. Browse CSD’s full peptide range for complete sourcing.
